Welcome

Pre-Open

RegMed Investors’ (RMi) pre-open: Another econ, PCE

June 27, 2025

Inflation data … moves which dial?

Breaking: Prices that consumers pay rose slightly in May, while the annual inflation rate moved further away from the Fed’s target < Commerce Department>

The personal consumption expenditures price index, the Fed’s primary inflation reading, rose a seasonally adjusted 0.1% for the month, putting the annual inflation rate at 2.3%. Economists had been looking for respective levels of 0.1% and 2.3%.
Excluding food and energy, core PCE posted respective readings of 0.2% and 2.7%, compared to estimates for 0.1% and 2.6%.
Fed policymakers consider core to be a better measure of long-term trends because of historic volatility in the 2 categories.

No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief

Never leave an investor uninformed!

Out and About

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): PONZI Scheme at its best or was convicted Bernie Madoff also resurrected

June 23, 2025

Escape, escape, run fast ... NO trust in this management team of connivers

6/20/25 - Back at it, The Harvard Apparatus RT (OTCQB: HRGN) the pump of share pricing is BACK in with 5475 shares trading up (+$0.14) after weekly session barely or the usual no shares trading. If I had to guess <usually right> today’s investor meeting did NOT meet expectation <as usual>. Post Thursday’s holiday, Wednesday’s share pricing $0.00 after Tuesday’s +$0.05 <+995 shares traded> and Monday’s $0.00). Back to my admonition, a Ponzi scheme!

6/4/25 ... Questions exist as stock dives in afternoon -$0.7141 to $0.93 with 5000 shares traded and suddenly is “resurrected” at the close to +$0.01 with 9,250 shares traded – PONZI Scheme at its best or was convicted Bernie Madoff also resurrected in DST Capital (run by HRGN’s President)???

No partner, No cash, NO runway, extensive liabilities and debts to past employee and university associations

Harvard Apparatus RT (OTCQB: HRGN) Net loss of -$1.659 M or -$0.10 per share, revenue of $45 K, cash position of $1.728 M with a Q2/25 runway; accumulated deficit of -$101.3 M, liabilities of -$11.9 K in addition to -$207 K owed to former employees, and 161 K to Un of Pitt and Yale <No release, 8-K, filed 5/14>.
What about past (still unpaid for months of work) consultants with documentation!! Going Concern status still in effect.

Closing Bell

RegMed Investors (RMi) Closing Bell: Econ’s inflation data was hotter than expected as May PCE pushes rate cuts odds lower

June 27, 2025

Yet again, we have to give-back on share pricing flicking’ the switch on share pricing issues, as trade talks end with Canada

Breadth was negative, with an advance/decline line of 10-to-21 on my covered Nasdaq listings; I'll be cautious cherry-picking exposure

Remain cautious, with your portfolio tilted toward cash

When you want to decant or fill your portfolio carafe, always consider it, a glass half-full

TGIF

Never leave an investor uninformed!

Research Notes

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): PONZI Scheme at its best or was convicted Bernie Madoff also resurrected

June 23, 2025

Escape, escape, run fast ... NO trust in this management team of connivers 6/20/25 - Back at it, The Harvard Apparatus RT (OTCQB: HRGN) the pump of share pricing is BACK in with 5475 shares trading up (+$0.14) after weekly session barely or the usual no shares trading. If I had to guess <usually right> today’s investor meeting did NOT meet expectation <as usual>. Post Thursday’s holiday, Wednesday’s share pricing $0.00 after Tuesday’s +$0.05 <+995 shares traded> and Monday’s $0.00). Back to my admonition, a Ponzi scheme! 6/4/25 ... Questions exist as stock dives in afternoon -$0.7141 to $0.93 with 5000 shares traded and suddenly is “resurrected” at the close to +$0.01 with 9,250 shares traded – PONZI Scheme at its best or was convicted Bernie Madoff also resurrected in DST Capital (run by HRGN’s President)??? No partner, No cash, NO runway, extensive liabilities and debts to past employee and university associations Harvard Apparatus RT (OTCQB: HRGN) Net loss of -$1.659 M or -$0.10 per share, revenue of $45 K, cash position of $1.728 M with a Q2/25 runway; accumulated deficit of -$101.3 M, liabilities of -$11.9 K in addition to -$207 K owed to former employees, and 161 K to Un of Pitt and Yale <No release, 8-K, filed 5/14>. What about past (still unpaid for months of work) consultants with documentation!! Going Concern status still in effect.

News: RegMedInvestors (RMi) Research Note: Verve Therapeutics (VERV) to be acquired by Eli Lilly (LLY)

June 17, 2025

Gene therapy companies are riding a new waave ... Verve Therapeutics (VERV +$4.79 or +76.31 to $11.06) rallied after the gene editing company agreed to be acquired by Eli Lilly (LLY -$9.13 or -1.15% to $798.28) or $10.50 per share, a premium of 67.5% on the company’s last close. The deal, which is worth up to $1.3 billion, is expected to close in Q3/25. The 2 companies were already partnered on a handful of 1-time treatments for cardiovascular diseases. VERV's leading program would use gene editing to permanently turn off the PCSK9 gene. The gene makes a protein that, when elevated, leads to high cholesterol. LLY also agreed to pay an additional $3 per share in a contingent value right. Lilly will pay the CVR when the first patient receives Verve's leading drug in a U.S. P3 study for atherosclerotic cardiovascular disease.

RegMed Investors (RMi) Financing: Sangamo Therapeutics (SGMO) prices 12,235 M share offering at $0.50 to raise $23 M

May 13, 2025

SGMO is trading at $0.449 down -$0.2967 or -39.7% Cantor is acting as sole book-running manager for the offering.

Research Notes

June 23, 2025 RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): PONZI Scheme at its best or was convicted Bernie Madoff also resurrected Escape, escape, run fast ... NO trust in this management team of connivers 6/20/25 - Back at it, The Harvard Apparatus RT (OTCQB: HRGN) the pump of share pricing is BACK in with 5475 shares trading up (+$0.14) after weekly session barely or the usual no shares trading. If I had to guess <usually right> today’s investor meeting did NOT meet expectation <as usual>. Post Thursday’s holiday, Wednesday’s share pricing $0.00 after Tuesday’s +$0.05 <+995 shares traded> and Monday’s $0.00). Back to my admonition, a Ponzi scheme! 6/4/25 ... Questions exist as stock dives in afternoon -$0.7141 to $0.93 with 5000 shares traded and suddenly is “resurrected” at the close to +$0.01 with 9,250 shares traded – PONZI Scheme at its best or was convicted Bernie Madoff also resurrected in DST Capital (run by HRGN’s President)??? No partner, No cash, NO runway, extensive liabilities and debts to past employee and university associations Harvard Apparatus RT (OTCQB: HRGN) Net loss of -$1.659 M or -$0.10 per share, revenue of $45 K, cash position of $1.728 M with a Q2/25 runway; accumulated deficit of -$101.3 M, liabilities of -$11.9 K in addition to -$207 K owed to former employees, and 161 K to Un of Pitt and Yale <No release, 8-K, filed 5/14>. What about past (still unpaid for months of work) consultants with documentation!! Going Concern status still in effect. June 17, 2025 News: RegMedInvestors (RMi) Research Note: Verve Therapeutics (VERV) to be acquired by Eli Lilly (LLY) Gene therapy companies are riding a new waave ... Verve Therapeutics (VERV +$4.79 or +76.31 to $11.06) rallied after the gene editing company agreed to be acquired by Eli Lilly (LLY -$9.13 or -1.15% to $798.28) or $10.50 per share, a premium of 67.5% on the company’s last close. The deal, which is worth up to $1.3 billion, is expected to close in Q3/25. The 2 companies were already partnered on a handful of 1-time treatments for cardiovascular diseases. VERV's leading program would use gene editing to permanently turn off the PCSK9 gene. The gene makes a protein that, when elevated, leads to high cholesterol. LLY also agreed to pay an additional $3 per share in a contingent value right. Lilly will pay the CVR when the first patient receives Verve's leading drug in a U.S. P3 study for atherosclerotic cardiovascular disease. May 13, 2025 RegMed Investors (RMi) Financing: Sangamo Therapeutics (SGMO) prices 12,235 M share offering at $0.50 to raise $23 M SGMO is trading at $0.449 down -$0.2967 or -39.7% Cantor is acting as sole book-running manager for the offering. March 10, 2025 Beam Therapeutics (BEAM) an offering of 16,151,686 shares priced at $28.48 per share including pre-funded warrants to purchase 1,404,988 shares of common stock at an offering price of $28.47 per pre-funded warrant with an exercise price of $0.01 per share. BEAM closed Friday at $1.23 to $28.48 with a pre-open indication of $2.57 or +0.02% to $31.05 Gross proceeds from the offering are expected to be approximately $500.0 million expected to close on or about 3/11/2525 February 18, 2025 RegMedInvestors (RMi) Financing Note: Solid Biosciences (SLDB) priced 35.739 M share offering with warrants 35.739 M shares were priced at $4.30 with 13.88 M warrants priced at $4.029 Tuesday SLDB jumped +$1.27 to $5.30 The financing includes new and existing investors, including Adage Capital Partners LP, Bain Capital Life Sciences, Invus, Perceptive Advisors, RA Capital Management, TCGX, Venrock Healthcare Capital Partners, Vestal Point Capital, a U.S.-based life-sciences focused institutional investor, a major mutual fund and a large investment management firm.

Indication intelligence, analysis and sector perception

Weekend Recap

Earnings